Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Di Napoli

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Materials Science & Engineering. C, Materials for Biological Applications|April 4, 2021
Multifunctional mats by antimicrobial nanoparticles decoration for bioinspired smart wound dressing solutionsJ Avossa, G Pota, G Vitiello, et al.
Beneficial Microbes|November 27, 2020
Characterisation of EFV12 a bio-active small peptide produced by the human intestinal isolate <i>Lactobacillus gasseri</i> SF1109M Di Napoli, B Di Luccia, G Vitiello, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 13, 2018
Trabectedin in Ovarian Cancer: is it now a Standard of Care?J Ventriglia, I Paciolla, S C Cecere, et al.
Gynecologic Oncology|January 18, 2017
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatinA Bergamini, C Pisano, M Di Napoli, et al.
European Review for Medical and Pharmacological Sciences|July 30, 2013
Intravesical chemo-immunotherapy in non muscle invasive bladder cancerD Leopardo, S C Cecere, M Di Napoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialD Lorusso, G Scambia, S Pignata, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2025
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)C D'Alterio, G Rea, M Napolitano, et al.
Scientific Reports|September 4, 2015
Monomeric C-reactive protein--a key molecule driving development of Alzheimer's disease associated with brain ischaemia?M Slevin, S Matou, Y Zeinolabediny, et al.
ESMO Open|April 25, 2025
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trialG Schepisi, M Urbini, C Casadei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Materials Science & Engineering. C, Materials for Biological Applications|April 4, 2021
Multifunctional mats by antimicrobial nanoparticles decoration for bioinspired smart wound dressing solutionsJ Avossa, G Pota, G Vitiello, et al.
Beneficial Microbes|November 27, 2020
Characterisation of EFV12 a bio-active small peptide produced by the human intestinal isolate <i>Lactobacillus gasseri</i> SF1109M Di Napoli, B Di Luccia, G Vitiello, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 13, 2018
Trabectedin in Ovarian Cancer: is it now a Standard of Care?J Ventriglia, I Paciolla, S C Cecere, et al.
Gynecologic Oncology|January 18, 2017
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatinA Bergamini, C Pisano, M Di Napoli, et al.
European Review for Medical and Pharmacological Sciences|July 30, 2013
Intravesical chemo-immunotherapy in non muscle invasive bladder cancerD Leopardo, S C Cecere, M Di Napoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialD Lorusso, G Scambia, S Pignata, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2025
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)C D'Alterio, G Rea, M Napolitano, et al.
Scientific Reports|September 4, 2015
Monomeric C-reactive protein--a key molecule driving development of Alzheimer's disease associated with brain ischaemia?M Slevin, S Matou, Y Zeinolabediny, et al.
ESMO Open|April 25, 2025
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trialG Schepisi, M Urbini, C Casadei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
Pageof 3